Social Listening Investigations Can Provide Insights into Patients’ Perception of Lung Cancer Treatment

Web Exclusives —December 22, 2021

Categories:

Lung Cancer

Social media has become an important aspect of healthcare information creation and sharing. Health data collected by analysis of online forums, blogs, videos, and direct networking sites minimize the Hawthorne effect frequently found in biomedical research.1 The Hawthorne effect occurs when patients who are asked to self-report experiences through survey or interview questions are influenced by the setting.1 This may cause them to report what they perceive as the expected opinion rather than their true opinion, confounding research outcomes.1 By using social media to investigate patient opinions, biomedical researchers can rapidly collect real-world data from a larger and more diverse population than found in traditional research methods and potentially minimize the Hawthorne effect.1

Using this approach in lung cancer research has the potential to advance treatment for this disease. Lung cancer is the most common cancer worldwide and is diagnosed in 2 million patients annually. Recent advances in lung cancer treatment have offered hope for prolonged survival, but the 5-year survival rate of 18.6% is much lower than many other cancers.2 Rodrigues and colleagues conducted an observational study using a social listening approach to investigate patient, caregiver, and healthcare professionals’ perceptions of lung cancer. The results of this study were presented at the European Society for Medical Oncology Congress 2021.

Data from open-access forums, blogs, and social networking sites were collected retrospectively from 14 European countries using social media aggregator tools after searching the terms “lung cancer” and “non-small cell lung cancer.” The majority (91%) of patients had late-stage lung cancer and were between the ages of 51 and 70 years. Automated algorithms and manual review were used to filter the data followed by random sampling to create the final data set from 1360 conversations. Patients and caregivers generated 42% of the conversations and healthcare professionals generated 14% of conversations. Healthcare professionals primarily used technical language, while patients and caregivers primarily used colloquial language in discussions. Lung cancer treatment was the most frequent discussion topic, with causes and diagnosis being the second and third most frequently discussed topics, respectively. Chemotherapy had the most negative perception, with 28% of sentiments being negative and 12% positive. Immunotherapy and targeted therapies had higher positive sentiments, with both having 47% positive sentiment. This was attributed to the perceptions of having longer survival outcomes and fewer side effects with use of these therapies. When clinical end point conversations were analyzed, prolonged survival was mentioned 47% of the time and overall survival was mentioned 30% of the time by both patients/caregivers and healthcare professionals. Analysis of treatment discontinuation conversations revealed exhaustion of treatment options, and intolerable side effects were the primary citations for discontinuation of treatment. Treatment changes were driven by relapse, metastatic disease, and treatment inefficacy.

Social listening can provide healthcare professionals and researchers with valuable insight and information concerning patients’ unmet needs to direct further research.

Source

Rodrigues A, Chauhan J, Sagkriotis A, et al. Using social listening to understand stakeholder perceptions of the patient journey in lung cancer. Ann Oncol. 2021;32(suppl_5):S1025.

References

  1. McDonald L, Behl V, Sundar V, et al. Validity of social media for assessing treatment patterns in oncology patients: a case study in melanoma. JAMIA Open. 2019;2:416-422.
  2. American Lung Association. Lung cancer fact sheet. Updated May 27, 2020. www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet. Accessed December 1, 2021.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country